{"entity":{"id":"nct06245915","kind":"trial","name":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","aka":[],"tldr":"A phase 1/2 trial of AB-2100 in renal cell carcinoma, run by Arsenal Biosciences, Inc., active and no longer recruiting.","summary":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) is a phase 1/2 interventional study registered as NCT06245915 by Arsenal Biosciences, Inc., with 37 participants enrolled, started 2024-02-26 and due to reach its primary completion in 2026-03-31. Interventions recorded: AB-2100.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06245915","url":"https://clinicaltrials.gov/study/NCT06245915"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arsenal-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06245915","phase":"1/2","setting":"An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients With Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)","sponsor":"Arsenal Biosciences, Inc.","enrolled":37,"outcomes":[]},"route":"/trials/nct06245915/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"company":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"}]}}